

Note: This document is a translation of the original Japanese version and provided for reference purposes only. In the event of any discrepancy between the Japanese original and this English translation, the Japanese original shall prevail.

Press Release



ASKA Becomes DX-Certified Operator Recognized by METI

TOKYO, August 20, 2025 – ASKA Pharmaceutical Holdings Co., Ltd. (TSE: 4886, Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi) is pleased to announce that ASKA has been recognized as a “DX-Certified Operator” based on the DX (Digital Transformation) Certification Program established by the Ministry of Economy, Trade and Industry.



The DX Certification Program is to review and certify operators that are strategically engaged in digital transformation (DX) based on the Act on Promotion of Information Processing. Certified operators are evaluated as having established systems that meet or exceed specific standards in areas such as digital strategies aligned with management vision, organizational structure, IT governance, and human resource development.

ASKA will promote DX based on the following four pillars as part of its DX strategy for 2030.

- Human resource development: In addition to improving the IT literacy of all employees, ASKA will select and train “DX promotion managers” from each department to support field-led reforms.
- Utilization of RPA: ASKA will improve productivity and stabilize business quality by automating routine tasks.
- Utilization of AI technology: ASKA will incorporate generative AI into its operations to promote advanced information processing and decision-making.
- On-site improvement and development: ASKA will utilize no-code and low-code tools to build a system that enables each department to independently optimize its operations.

Furthermore, ASKA will establish a data-driven management environment that leverages accumulated data and advanced technology to enhance the quality and speed of decision-making.

The purpose of obtaining this certification is to strengthen its internal DX promotion system and clearly demonstrate its commitment to external stakeholders. Taking this opportunity, ASKA will enhance operational efficiency throughout the entire drug discovery, development, production,

and sales process, aiming for sustainable growth by focusing on the core business.

ASKA will continue to pursue continuous challenges toward the realization of our DX vision, which is to “contribute to people's health and society by strengthening the value chain of pharmaceutical provision through the use of data and digital technology to review traditional business processes and create new value”.

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.

Corporate Planning Department

Tel: +81-3-5484-8366

Email: kouhou@aska-pharma.co.jp